Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer (Q39066439)

8 September 2017

title

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. (English)

1 reference

8 September 2017

1 reference

Josep Tabernero Caturla

series ordinal

1 reference

8 September 2017

Sabine Tejpar

0 references

Scott Kopetz

0 references

Justin Guinney

1 reference

8 September 2017

Rodrigo Dienstmann

1 reference

8 September 2017

Louis Vermeulen

series ordinal

1 reference

8 September 2017

language of work or name

English

0 references

publication date

4 January 2017

1 reference

8 September 2017

published in

Nature Reviews Cancer

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

8 September 2017

page(s)

79-92

1 reference

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Colorectal cancer statistics, 2014.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Colorectal Cancer on the Decline--Why Screening Can't Explain It All.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

First-line chemotherapy for mCRC—a review and evidence-based algorithm.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Molecular Genetics of Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

A genetic model for colorectal tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

31 March 2020

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Genetic alterations during colorectal-tumor development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

The consensus coding sequences of human breast and colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Comprehensive molecular characterization of human colon and rectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Recurrent R-spondin fusions in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

The chromosomal instability pathway in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Molecular dissection of microsatellite instable colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Serrated lesions of the colorectum: review and recommendations from an expert panel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

RNF43 is frequently mutated in colorectal and endometrial cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Identification and characterization of RET fusions in advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

The landscape of kinase fusions in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

A colorectal cancer classification system that associates cellular phenotype and responses to therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

The consensus molecular subtypes of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Stromal contribution to the colorectal cancer transcriptome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Cancer classification using the Immunoscore: a worldwide task force

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Ulcerative colitis-associated colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Detection of circulating tumor DNA in early- and late-stage human malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

The genomic landscape of response to EGFR blockade in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Integrative genomic and transcriptomic characterization of matched primary and metastatic liver and colorectal carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

A Big Bang model of human colorectal tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Heterogeneity of driver genes and therapeutic implications in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

HER2 activating mutations are targets for colorectal cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients withKRASwild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

TGFβ inhibition prior to hypofractionated radiation enhances efficacy in preclinical models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Combination cancer immunotherapies tailored to the tumour microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Immunogenic death of colon cancer cells treated with oxaliplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Cerebral hemorrhage, warfarin, and intravenous tPA: the real risk is not treating

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Prospective derivation of a living organoid biobank of colorectal cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Wnt addiction of genetically defined cancers reversed by PORCN inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.126

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28050011

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRC.2016.126

1 reference

8 September 2017

1 reference